IMPACT trial: angiographic and intravascular ultrasound observations of the first human experience with mycophenolic acid-eluting polymer stent system
Catheter Cardiovasc Interv
; 66: 491-495, 10 de novembro de 2005.
Article
en En
| SES-SP, SESSP-IDPCPROD, SES-SP
| ID: biblio-1061834
Biblioteca responsable:
BR79.1
Ubicación: BR79.1
RESUMO
The purpose of the study was to examine the safety and efficacy of two different formulations of mycophenolic acid (MPA)-eluting Duraflex stents on coronary de novo lesions. Recent data indicate that local delivery of MPA in the porcine overstretch coronary
ABSTRACT
model significantly reduces neointimal hyperplasia (NIH). Patients were divided into three consecutive groups. The first (n 5 50) and second (n 5 55) groups received moderate- and slow-release MPA-eluting Duraflex stent, respectively. The last group (n 5 50) received the bare metal Duraflex stent. Clinical, angiographic, and intravascular
Buscar en Google
Colección:
06-national
/
BR
Base de datos:
SES-SP
/
SESSP-IDPCPROD
Asunto principal:
Stents
/
Stents Liberadores de Fármacos
/
Ácido Micofenólico
Idioma:
En
Revista:
Catheter Cardiovasc Interv
Año:
2005
Tipo del documento:
Article